Business Context and Reporting Period
This Form 8-K filing by Bausch + Lomb Corporation (BLCO) covers events occurring on September 29, 2023. The report details the completion of a major strategic acquisition and the associated financing transactions required to fund the deal.
Key Financial Metrics and Transactions
The filing focuses on capital structure changes rather than operating performance metrics such as revenue or profit margins. Key financial figures include:
- Debt Issuance: Completed an offering of $1.4 billion aggregate principal amount of 8.375% Senior Secured Notes due 2028.
- Term Loan Facility: Borrowed $500 million in First Incremental Term Loans under an amended Credit Agreement.
- Interest Rates:
- Notes: Fixed at 8.375% per annum, payable semi-annually.
- Term Loans: Variable rate based on Base Rate + 3.00% or Term SOFR + 4.00%.
- Use of Proceeds: Funds were utilized to finance the acquisition of XIIDRA and other ophthalmology assets from Novartis, pay related fees and expenses, and for general corporate purposes including the repayment of existing debt.
Material Changes Versus Prior Period
The primary material change is the significant increase in leverage to fund the acquisition of Novartis assets:
- Acquisition Completion: Finalized the purchase of XIIDRA and certain other ophthalmology assets from Novartis.
- Capital Structure: Added $1.9 billion in new debt obligations ($1.4 billion in notes and $500 million in term loans).
- Covenants: The new Indenture and Amended Credit Agreement impose restrictions on incurring additional indebtedness, making restricted payments, creating liens, and engaging in mergers or asset sales.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The filing confirms the successful execution of the acquisition strategy. The company intends to file an amendment to this Form 8-K within 71 days to include required financial statements and pro forma information regarding the acquisition.
Risks and Contingencies:
- Debt Service Obligations: The Notes mature on October 1, 2028, with interest payments beginning April 1, 2024. The Term Loans mature on September 29, 2028.
- Redemption Provisions: The Notes are redeemable at the company's option after October 1, 2025. Prior to that date, redemption is possible at a "make-whole" premium or up to 40% using equity offering proceeds.
- Change of Control: Holders may require the company to repurchase the Notes at 101% of principal plus accrued interest upon a change of control.
- Subordination: The Notes are structurally subordinated to the indebtedness of non-guarantor subsidiaries.
Investor Verification Checklist
- Verify the final purchase price and specific assets included in the Novartis acquisition once the amended Form 8-K with financial statements is filed.
- Review the full text of the Indenture (Exhibit 4.1) and Amended Credit Agreement (Exhibit 10.1) for detailed covenant restrictions.
- Monitor the company's liquidity position to ensure it can meet the new semi-annual interest payments starting April 2024.
- Assess the impact of the $1.9 billion debt increase on the company's credit rating and future borrowing capacity.